BioStem Technologies Inc., a regenerative medicine company specializing in perinatal tissue allograft products, announced that company management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET, with live and archived webcasts available through the company's investor relations website at https://ir.biostemtechnologies.com.
This conference appearance is significant because it provides BioStem with a platform to showcase its proprietary processing technologies and expanding product portfolio to healthcare investors and industry professionals. The company's BioRetain®, CryoTek® and SteriTek® technologies are designed to preserve the natural properties of perinatal tissues, making them suitable for clinical applications across various medical specialties.
BioStem's participation in this prominent healthcare conference underscores the growing importance of regenerative medicine in addressing complex medical challenges. The company's products, including Neox®, Clarix®, VENDAJE® and American Amnion™, represent innovative approaches to tissue repair and regeneration that could potentially reduce recovery times and improve patient outcomes in numerous clinical settings.
The company's quality management system has been accredited by the American Association of Tissue Banks, with procedures established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. This accreditation provides assurance to healthcare providers and patients about the safety and quality of BioStem's allograft products.
For investors and industry observers, BioStem's presentation offers insights into the company's growth strategy, research initiatives, and commercial expansion in the regenerative medicine sector. The regenerative medicine market continues to expand as healthcare systems seek advanced solutions for wound care, orthopedic applications, and other medical needs where traditional treatments have limitations.
Interested parties can access additional information about BioStem Technologies through the company's website at https://biostemtechnologies.com. The company maintains a newsroom for updates at https://tinyurl.com/bsemnewsroom, providing stakeholders with ongoing information about developments in the regenerative medicine field.
